Paragon Associates & Paragon Associates II Joint Venture’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-46,646
| Closed | -$4.69M | – | 18 |
|
|
2021
Q3 | $4.69M | Sell |
46,646
-21,454
| -32% | -$2.16M | 5.31% | 9 |
|
|
2021
Q2 | $9.64M | Sell |
68,100
-31,900
| -32% | -$4.51M | 12.82% | 2 |
|
|
2021
Q1 | $9.97M | Sell |
100,000
-40,000
| -29% | -$3.99M | 15.2% | 3 |
|
|
2020
Q4 | $17.3M | Sell |
140,000
-10,000
| -7% | -$1.24M | 26.61% | 1 |
|
|
2020
Q3 | $14.6M | Sell |
150,000
-51,000
| -25% | -$4.97M | 19.62% | 3 |
|
|
2020
Q2 | $31.4M | Sell |
201,000
-2,500
| -1% | -$390K | 34.45% | 1 |
|
|
2020
Q1 | $29.4M | Sell |
203,500
-18,500
| -8% | -$2.67M | 31.55% | 1 |
|
|
2019
Q4 | $45.4M | Sell |
222,000
-23,000
| -9% | -$4.7M | 25.5% | 1 |
|
|
2019
Q3 | $19.7M | Hold |
245,000
| – | – | 15.18% | 1 |
|
|
2019
Q2 | $23.1M | Hold |
245,000
| – | – | 17.8% | 1 |
|
|
2019
Q1 | $20.9M | Hold |
245,000
| – | – | 19.75% | 1 |
|
|
2018
Q4 | $13.7M | Buy |
245,000
+5,000
| +2% | +$281K | 18.25% | 1 |
|
|
2018
Q3 | $19.6M | Sell |
240,000
-10,000
| -4% | -$818K | 22.37% | 1 |
|
|
2018
Q2 | $8.74M | Hold |
250,000
| – | – | 11.36% | 2 |
|
|
2018
Q1 | $5.13M | Hold |
250,000
| – | – | 7.47% | 5 |
|
|
2017
Q4 | $7.08M | Hold |
250,000
| – | – | 5.89% | 9 |
|
|
2017
Q3 | $7.78M | Hold |
250,000
| – | – | 6.64% | 7 |
|
|
2017
Q2 | $7.91M | Hold |
250,000
| – | – | 8.98% | 6 |
|
|
2017
Q1 | $5.66M | Hold |
250,000
| – | – | 6.09% | 7 |
|
|
2016
Q4 | $5.46M | Buy |
250,000
+100,000
| +67% | +$2.18M | 7.26% | 5 |
|
|
2016
Q3 | $3.95M | Hold |
150,000
| – | – | 4.57% | 10 |
|
|
2016
Q2 | $2.96M | Buy |
+150,000
| New | +$2.96M | 2.9% | 11 |
|